Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction (EMMY-Trial) – a phase III Study

X
Trial Profile

Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction (EMMY-Trial) – a phase III Study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Empagliflozin (Primary)
  • Indications Myocardial infarction
  • Focus Biomarker; Therapeutic Use
  • Acronyms EMMY-Trial
  • Most Recent Events

    • 06 Oct 2023 Results of sub-group analysis assessing the effects of SGLT2i after acute myocardial infarction in people with and without type 2 diabetes, presented at the 59th Annual Meeting of the European Association for the Study of Diabetes.
    • 29 Aug 2022 Primary endpoint N-terminal pro-hormone of brain natriuretic peptide (NT-proBNP) change over 26 weeks has been met according to results published in the European Heart Journal
    • 29 Aug 2022 Results published in the European Heart Journal
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top